Target intelligence / Profile preview

Outer membrane protein OprM (OprM)

Target
OprM
Molecular classification
Transporter, Outer membrane protein, Outer membrane factor (OMF) family
01

Overview

Outer membrane protein OprM is a vital component of the tripartite multidrug efflux systems in the Gram-negative bacterium Pseudomonas aeruginosa, serving as the exit duct for the MexAB-OprM, MexCD-OprJ, and MexXY-OprM complexes (UniProt, 2024; Li et al., 2015). As a member of the Outer Membrane Factor (OMF) family, OprM forms a trimeric channel that spans the outer membrane, allowing the expulsion of diverse substrates, including antibiotics, detergents, and dyes, directly from the periplasm or cytoplasm to the extracellular space (Nakashima et al., 2013). This efflux activity is a primary driver of multidrug resistance (MDR) in P. aeruginosa, rendering many standard-of-care antibiotics, such as carbapenems and fluoroquinolones, ineffective (Lomovskaya et al., 2001). Beyond antibiotic resistance, OprM is implicated in the secretion of quorum-sensing molecules and virulence factors, which are essential for the pathogen's survival and pathogenicity during infection (Minagawa et al., 2012). Consequently, OprM is considered a high-value therapeutic target for efflux pump inhibitors (EPIs) designed to restore antibiotic efficacy (Misra et al., 2015). Current research focuses on small molecules like D13-9001 that can bind to the pump assembly and block the efflux process, though clinical translation remains challenging due to potential toxicity and delivery hurdles (Nakashima et al., 2013; Misra et al., 2015).

Other names
OprMOuter membrane factor OprMMexA-MexB-OprM exit ductTolC-like protein OprMOuter membrane factor (OMF)
02

Mechanism of action

Efflux pump inhibition via blocking the exit channel or disrupting the assembly of the tripartite pump complex

03

Biological functions

Multidrug effluxAntibiotic resistanceProtein secretionCellular homeostasisQuorum sensing
04

Disease associations

InfectionCystic fibrosisHospital-acquired pneumoniaSepsis
05

Safety considerations

Toxicity of inhibitors to host cellsOff-target inhibition of human transportersPoor penetration of the Gram-negative outer membraneRapid development of compensatory mutations in pump regulatory genes
06

Interacting drugs

Phenylalanine-arginine beta-naphthylamide (PAβN)

3 more in the full profile.

07

Biomarkers

oprM gene expression levelsMexAB-OprM protein levelsAntibiotic MIC reduction in the presence of efflux pump inhibitors

Beyond the preview

Go deeper on Outer membrane protein OprM (OprM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Outer membrane protein OprM (OprM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call